Recent Comments

Comment RSS

microRNA News and Research RSS Feed - microRNA News and Research

In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.

Hepatitis C Virus therapeutics development landscape continues to inflate

20. November 2009 01:06
Research and Markets (http://www.researchandmarkets.com/research/f6bf5e/hepatitis_c_virus) has announced the addition of the "Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities" report to their offering. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , ,

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

18. November 2009 07:38
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. [More]

Asuragen enters into an exclusive agreement with Life Technologies

18. November 2009 04:13
Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). [More]

Posted in: Business / Finance | Device / Technology News

Tags: , , , , , , ,

Press conference highlights emerging treatments in pancreatic cancer

18. November 2009 03:30
As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. [More]

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

17. November 2009 10:42
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions. [More]

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

12. November 2009 08:09
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today. [More]

USPTO issues patent for Rosetta Genomics' human microRNA miR-193b

6. November 2009 03:36
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO. [More]

Posted in: Medical Science News | Medical Patent News

Tags: , , , , , , , ,

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

5. November 2009 07:41
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi. [More]

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

4. November 2009 08:01
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007. [More]

Findings may lead to new drug therapies to reduce breast cancer metastasis

4. November 2009 01:21
Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer. [More]

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

2. November 2009 07:48
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”). [More]

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

2. November 2009 03:38
InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. [More]

Posted in: Medical Science News

Tags: , , ,

IGR Genomic Center awarded ISO 9001 certification

30. October 2009 07:29
The Institut de cancérologie Gustave Roussy (IGR) France announced today that its Genomic Center has been awarded ISO 9001 certification for quality management and compliance to the highest standards of quality by Association Française de Normalisation (AFNOR), France’s national organization for standardization and certification. [More]

Posted in: Device / Technology News | Medical Science News

Tags: , , , ,

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

29. October 2009 08:53
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam. [More]

GeneGo to launch new web site with high quality pathway content

29. October 2009 07:45
GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism. [More]

Posted in: Device / Technology News

Tags: , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.